- Home
- LEA vs IONS Comparison
LEA vs IONS Comparison
Compare LEA & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEA
- IONS
- Stock Information
- Founded
- LEA 1917
- IONS 1989
- Country
- LEA United States
- IONS United States
- Employees
- LEA N/A
- IONS N/A
- Industry
- LEA Auto Parts:O.E.M.
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- LEA Consumer Discretionary
- IONS Health Care
- Exchange
- LEA Nasdaq
- IONS Nasdaq
- Market Cap
- LEA 5.3B
- IONS 6.0B
- IPO Year
- LEA N/A
- IONS 1991
- Fundamental
- Price
- LEA $88.75
- IONS $28.71
- Analyst Decision
- LEA Buy
- IONS Buy
- Analyst Count
- LEA 11
- IONS 19
- Target Price
- LEA $126.09
- IONS $59.24
- AVG Volume (30 Days)
- LEA 879.3K
- IONS 1.6M
- Earning Date
- LEA 04-29-2025
- IONS 05-06-2025
- Dividend Yield
- LEA 3.47%
- IONS N/A
- EPS Growth
- LEA N/A
- IONS N/A
- EPS
- LEA 8.97
- IONS N/A
- Revenue
- LEA $23,306,000,000.00
- IONS $705,138,000.00
- Revenue This Year
- LEA N/A
- IONS N/A
- Revenue Next Year
- LEA $3.65
- IONS $25.71
- P/E Ratio
- LEA $9.90
- IONS N/A
- Revenue Growth
- LEA N/A
- IONS N/A
- 52 Week Low
- LEA $85.29
- IONS $27.00
- 52 Week High
- LEA $145.05
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- LEA 38.81
- IONS 36.34
- Support Level
- LEA $85.29
- IONS $31.04
- Resistance Level
- LEA $97.62
- IONS $33.76
- Average True Range (ATR)
- LEA 2.92
- IONS 1.33
- MACD
- LEA -0.87
- IONS -0.54
- Stochastic Oscillator
- LEA 27.72
- IONS 22.09
About LEA Lear Corporation
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns most of its revenue from the seating segment.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.